The current study had the following limitations and strengths: biochemical remission was determined as a CRP < 10 mg/L, which might be less sensitive than fecal calprotectin; the study was monocentric and rather small but included a well-defined IBD population; and the prevalence of depression was too low to permit thorough analyses. This evidence concerns the gene CRP and inflammatory bowel disease.